CY1105459T1 - Συνθεσεις που πepιεχουν εποθιλονες και η χρηση τους για τη θepαπεια του καρκινοειδους συνδρομου - Google Patents
Συνθεσεις που πepιεχουν εποθιλονες και η χρηση τους για τη θepαπεια του καρκινοειδους συνδρομουInfo
- Publication number
- CY1105459T1 CY1105459T1 CY20061101280T CY061101280T CY1105459T1 CY 1105459 T1 CY1105459 T1 CY 1105459T1 CY 20061101280 T CY20061101280 T CY 20061101280T CY 061101280 T CY061101280 T CY 061101280T CY 1105459 T1 CY1105459 T1 CY 1105459T1
- Authority
- CY
- Cyprus
- Prior art keywords
- carcinoid syndrome
- combination
- compound
- treatment
- compositions containing
- Prior art date
Links
- 206010007270 Carcinoid syndrome Diseases 0.000 title abstract 3
- 229930013356 epothilone Natural products 0.000 title 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 206010052399 Neuroendocrine tumour Diseases 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 208000016065 neuroendocrine neoplasm Diseases 0.000 abstract 2
- 201000011519 neuroendocrine tumor Diseases 0.000 abstract 2
- QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical group [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 abstract 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 abstract 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 102000005157 Somatostatin Human genes 0.000 abstract 1
- 108010056088 Somatostatin Proteins 0.000 abstract 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 abstract 1
- 230000001142 anti-diarrhea Effects 0.000 abstract 1
- 229960004397 cyclophosphamide Drugs 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960002949 fluorouracil Drugs 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- -1 methoxy, ethoxy, amino, methylamino, dimethylamino , aminomethyl Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 abstract 1
- 229960000553 somatostatin Drugs 0.000 abstract 1
- 229960001052 streptozocin Drugs 0.000 abstract 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epoxy Compounds (AREA)
Abstract
Χρήση μιας ένωσης του χημικού τύπου (I) στην οποία το Α αντιπροσωπεύει Ο ή NRN, όπου το RN είναι υδρογόνο ή κατώτερο αλκύλιο, το R είναι υδρογόνο ή κατώτερο αλκύλιο, το R' είναι μεθύλιο, μεθόξυ, αιθόξυ, άμινο, μεθυλάμινο, διμεθυλάμινο, αμινομεθύλιο ή μεθυλθείο, και το Ζ είναι Ο ή ένας δεσμός, ή ένα φαρμακευτικώς αποδεκτό άλας εξ αυτών, μόνη της ή σε συνδυασμό με τουλάχιστον μία ένωση, η οποία επιλέχθηκε από την ομάδα η οποία αποτελείται από σωματοστατίνη ή ένα συνθετικό παράγωγο εξ αυτών, ιντερφερόνη, 5-φθοροουρακίλη, δοξορουβικίνη, κυκλοφωσφαμίδη, στρεπτοζοτοκίνη και ένα συνηθισμένο αντι - διαρροϊκό, για την παρασκευή ενός φαρμάκου για την θεραπεία του καρκινοειδούς συνδρόμου ή τουλάχιστον ενός νευροενδοκρινούς όγκου, μία μέθοδο για τη θεραπεία ενός θερμόαιμου ζώου, το οποίο έχει καρκινοειδές σύνδρομο και / ή τουλάχιστον έναν νευροενδοκρινή όγκο, έναν συνδυασμό, ο οποίος περιλαμβάνει μια ένωση του χημικού τύπου I όπως ορίστηκε πιο πάνω και τουλάχιστον μία ένωση η οποία επιλέχθηκε από την ομάδα η οποία παρουσιάστηκε πιο πάνω, και μία εμπορική συσκευασία η οποία περιλαμβάνει τον αναφερθέντα συνδυασμό.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34216701P | 2001-12-13 | 2001-12-13 | |
| US41599002P | 2002-10-04 | 2002-10-04 | |
| PCT/EP2002/014162 WO2003049734A1 (en) | 2001-12-13 | 2002-12-12 | Compositions comprising epothilones and their use for the treatment of carcinoid syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1105459T1 true CY1105459T1 (el) | 2010-04-28 |
Family
ID=26992855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061101280T CY1105459T1 (el) | 2001-12-13 | 2006-09-07 | Συνθεσεις που πepιεχουν εποθιλονες και η χρηση τους για τη θepαπεια του καρκινοειδους συνδρομου |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20050020647A1 (el) |
| EP (1) | EP1463504B1 (el) |
| JP (1) | JP4672257B2 (el) |
| KR (1) | KR101010767B1 (el) |
| CN (1) | CN1602192A (el) |
| AT (1) | ATE330602T1 (el) |
| BR (1) | BR0214917A (el) |
| CA (1) | CA2468994A1 (el) |
| CY (1) | CY1105459T1 (el) |
| DE (1) | DE60212710T2 (el) |
| DK (1) | DK1463504T3 (el) |
| ES (1) | ES2266610T3 (el) |
| HK (1) | HK1069983A1 (el) |
| HU (1) | HUP0402537A3 (el) |
| IL (1) | IL162166A0 (el) |
| MX (1) | MXPA04005712A (el) |
| NO (1) | NO332773B1 (el) |
| NZ (1) | NZ533378A (el) |
| PL (1) | PL209147B1 (el) |
| PT (1) | PT1463504E (el) |
| RU (1) | RU2341261C2 (el) |
| TW (1) | TWI287986B (el) |
| WO (1) | WO2003049734A1 (el) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2273083C (en) | 1996-12-03 | 2012-09-18 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| AU2003235761A1 (en) * | 2002-01-14 | 2003-07-24 | Novartis Ag | Combinations comprising epothilones and anti-metabolites |
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| BR0315169A (pt) * | 2002-10-09 | 2005-08-23 | Kosan Biosciences Inc | Referência cruzada a pedidos de patente relacionados |
| AU2004268377B2 (en) * | 2003-09-02 | 2008-06-26 | Novartis Ag | Cancer treatment with epothilones |
| US20050171167A1 (en) | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
| EP3566719A1 (en) | 2010-05-18 | 2019-11-13 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
| RU2633266C2 (ru) * | 2015-07-02 | 2017-10-11 | Рауф Ашрафович Ашрафов | Способ моделирования карциноидного синдрома |
| CN118742305A (zh) * | 2022-02-25 | 2024-10-01 | 阿迈特恩多有限公司 | 用于治疗疾病的口服奥曲肽 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4356270A (en) * | 1977-11-08 | 1982-10-26 | Genentech, Inc. | Recombinant DNA cloning vehicle |
| US4318477A (en) * | 1980-09-22 | 1982-03-09 | Kerpe Stase Z | Pharmaceutical package |
| US5753616A (en) * | 1986-11-10 | 1998-05-19 | Biopure Corporation | Method for producing a stable polymerized hemoglobin blood-substitute |
| DE3845000C2 (de) * | 1987-07-10 | 1998-11-19 | Novartis Ag | Anwendung von Octreotid zur Behandlung von Brustkrebs |
| DK0914102T3 (da) * | 1996-05-24 | 2006-01-09 | Angiotech Pharm Inc | Præparater og fremgangsmåder til behandling eller forebyggelse af syddomme i legemskanaler |
| US5969145A (en) * | 1996-08-30 | 1999-10-19 | Novartis Ag | Process for the production of epothilones and intermediate products within the process |
| DK1367057T3 (da) * | 1996-11-18 | 2009-01-19 | Biotechnolog Forschung Gmbh | Epothiloner E og F |
| US6495579B1 (en) * | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
| US6194181B1 (en) * | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| US6302838B1 (en) * | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
| DE19908760A1 (de) * | 1999-02-18 | 2000-08-24 | Schering Ag | Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung |
| AU2001266583A1 (en) * | 2000-05-26 | 2001-12-11 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
-
2002
- 2002-12-11 TW TW091135843A patent/TWI287986B/zh not_active IP Right Cessation
- 2002-12-12 US US10/498,069 patent/US20050020647A1/en not_active Abandoned
- 2002-12-12 NZ NZ533378A patent/NZ533378A/xx not_active IP Right Cessation
- 2002-12-12 MX MXPA04005712A patent/MXPA04005712A/es active IP Right Grant
- 2002-12-12 DK DK02790487T patent/DK1463504T3/da active
- 2002-12-12 PT PT02790487T patent/PT1463504E/pt unknown
- 2002-12-12 ES ES02790487T patent/ES2266610T3/es not_active Expired - Lifetime
- 2002-12-12 CA CA002468994A patent/CA2468994A1/en not_active Abandoned
- 2002-12-12 KR KR1020047009001A patent/KR101010767B1/ko not_active IP Right Cessation
- 2002-12-12 CN CNA028248341A patent/CN1602192A/zh active Pending
- 2002-12-12 RU RU2004121687/15A patent/RU2341261C2/ru not_active IP Right Cessation
- 2002-12-12 WO PCT/EP2002/014162 patent/WO2003049734A1/en active IP Right Grant
- 2002-12-12 BR BR0214917-6A patent/BR0214917A/pt not_active IP Right Cessation
- 2002-12-12 IL IL16216602A patent/IL162166A0/xx unknown
- 2002-12-12 HU HU0402537A patent/HUP0402537A3/hu unknown
- 2002-12-12 AT AT02790487T patent/ATE330602T1/de active
- 2002-12-12 JP JP2003550783A patent/JP4672257B2/ja not_active Expired - Fee Related
- 2002-12-12 DE DE60212710T patent/DE60212710T2/de not_active Expired - Lifetime
- 2002-12-12 PL PL369141A patent/PL209147B1/pl not_active IP Right Cessation
- 2002-12-12 EP EP02790487A patent/EP1463504B1/en not_active Expired - Lifetime
-
2004
- 2004-07-05 NO NO20042832A patent/NO332773B1/no not_active IP Right Cessation
-
2005
- 2005-03-29 HK HK05102627A patent/HK1069983A1/xx not_active IP Right Cessation
-
2006
- 2006-06-12 US US11/451,286 patent/US20060229345A1/en not_active Abandoned
- 2006-09-07 CY CY20061101280T patent/CY1105459T1/el unknown
-
2009
- 2009-05-07 US US12/437,226 patent/US20090246172A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1105459T1 (el) | Συνθεσεις που πepιεχουν εποθιλονες και η χρηση τους για τη θepαπεια του καρκινοειδους συνδρομου | |
| NO20021399L (no) | Kazolinderivater og deres anvendelse som farmasöyter | |
| AR046202A1 (es) | Compuestos nucleosidicos para el tratamiento de infecciones virales | |
| EA200500853A1 (ru) | 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака | |
| UA89788C2 (ru) | Композиция и способ борьбы с насекомыми или клещами, пиперидиновые производные | |
| DE60014076D1 (de) | Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid | |
| ECSP066405A (es) | Compuestos de aril o heteroaril amida | |
| DK1664041T3 (da) | Phenylcarboxamidforbindelser, der er egnede til behandling af smerter | |
| CY1105047T1 (el) | Ενωσεις πυριδοπυριμιδινονης, η μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις που τις περιεχουν | |
| CY1108295T1 (el) | Παραγωγα μονοσακχαριτη αβερμεκτινης τα οποια εχουν παρασιτοκτονες ιδιοτητες | |
| DE602004005323D1 (de) | Azidfreies verfahren zur herstellung von 1,2-diaminoverbindungen | |
| IT1311922B1 (it) | Composti farmaceutici. | |
| EE200000472A (et) | Kasvajavastased toimeained | |
| HRPK20030734B3 (en) | A combination comprising combretastatin and anticancer agents | |
| UY27979A1 (es) | Indoles sustituidos en posición 2,4 | |
| MY138466A (en) | Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders | |
| GEP20084306B (en) | Antibacterial indolone oxazolidinones, intermediates for their preparation and pharmaceutical compositions containing them | |
| ATE516031T1 (de) | Verbindungen gegen krebs | |
| FI935800A0 (fi) | Antidepressiva och mot Parkisons sjukdom verksamma foereningar | |
| CY1105345T1 (el) | Φαινυλαλκινια | |
| RU2365594C2 (ru) | Применение циклических пептидов анабенопептинового типа для лечения состояния, при котором полезно ингибирование карбоксипептидазы u, новые анабенопептиновые производные и их промежуточные соединения | |
| AR029072A1 (es) | Bis-(n,n'-bis-(2-haloetil)amino fosforamidatos, un procedimiento para su preparacion, una composicion farmaceutica, y el uso de los mismos para la manufactura de medicamentos antitumorales | |
| AU2058402A (en) | Use of lipopeptides or lipoproteins for treating lung infections and lung tumours | |
| BR0308911A (pt) | Composto, composição farmacêutica, métodos de tratamento de dor e de enxaqueca, e, uso de um composto | |
| TH69753A (th) | องค์ประกอบซึ่งประกอบด้วยอีโพทิโลน และการใช้ของพวกมันสำหรับการรักษาเนื้องอกของทางเดินอาหาร |